Nifty
:
24013.10
Sensex
:
76802.90
-154.90 (-0.64%)
-607.08 (-0.78%)
Nifty
Sensex
:
:
24013.10
76802.90
-154.90 (-0.64%)
-607.08 (-0.78%)

Mankind Pharma Ltd.

Pharmaceuticals & Drugs

Rating :
68/99

BSE: 543904 | NSE: MANKIND

NSE BSE
2414.20
19-Jun-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2417
  •  2430
  •  2395
  •  2406.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  484809
  •  1171423114
  •  2716.5
  •  1909.7

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 99,835.58
  • 52.19
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,05,164.62
  • N/A
  • 6.12

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 72.66%
  • 1.07%
  • 1.39%
  • FII
  • DII
  • Others
  • 10.24%
  • 11.50%
  • 3.14%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.96
  • 14.46
  • 11.74

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.81
  • 12.87
  • 9.69

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 13.91
  • 9.44
  • 15.72

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 51.91

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 7.73

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 31.60

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Net Sales
3,442.93
3,079.37
11.81%
3,567.20
3,198.79
11.52%
3,697.16
3,061.43
20.77%
3,570.35
2,867.85
24.50%
Expenses
2,513.05
2,396.18
4.88%
2,647.77
2,382.80
11.12%
2,775.83
2,214.24
25.36%
2,723.58
2,196.29
24.01%
EBITDA
929.88
683.19
36.11%
919.43
815.99
12.68%
921.33
847.19
8.75%
846.77
671.56
26.09%
EBIDTM
27.01%
22.19%
25.77%
25.51%
24.92%
27.67%
23.72%
23.42%
Other Income
114.29
251.33
-54.53%
72.75
77.00
-5.52%
91.87
109.06
-15.76%
79.88
99.40
-19.64%
Interest
141.75
190.54
-25.61%
157.20
220.93
-28.85%
169.68
7.10
2,289.86%
170.65
10.84
1,474.26%
Depreciation
223.08
230.87
-3.37%
222.60
187.17
18.93%
221.82
100.49
120.74%
218.68
102.69
112.95%
PBT
656.18
513.11
27.88%
505.79
484.89
4.31%
621.70
848.66
-26.74%
537.32
657.43
-18.27%
Tax
99.75
86.44
15.40%
95.12
110.46
-13.89%
103.84
189.98
-45.34%
95.87
122.86
-21.97%
PAT
556.43
426.67
30.41%
410.67
374.43
9.68%
517.86
658.68
-21.38%
441.45
534.57
-17.42%
PATM
16.16%
13.86%
11.51%
11.71%
14.01%
21.52%
12.36%
18.64%
EPS
13.43
10.20
31.67%
9.90
9.22
7.38%
12.39
16.31
-24.03%
10.62
13.39
-20.69%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
14,277.64
12,207.44
10,260.44
8,749.43
7,781.56
6,214.43
5,871.87
4,979.98
4,920.74
4,382.26
3,943.66
Net Sales Growth
16.96%
18.98%
17.27%
12.44%
25.22%
5.83%
17.91%
1.20%
12.29%
11.12%
 
Cost Of Goods Sold
4,052.12
3,489.04
3,198.47
2,913.64
2,421.73
1,780.60
1,878.07
1,721.34
1,670.59
1,585.80
1,550.56
Gross Profit
10,225.52
8,718.40
7,061.97
5,835.79
5,359.83
4,433.82
3,993.80
3,258.64
3,250.16
2,796.46
2,393.10
GP Margin
71.62%
71.42%
68.83%
66.70%
68.88%
71.35%
68.02%
65.43%
66.05%
63.81%
60.68%
Total Expenditure
10,660.23
9,186.97
7,745.27
6,847.50
5,791.01
4,565.32
4,427.16
4,054.95
3,927.09
3,531.31
3,184.58
Power & Fuel Cost
-
149.49
125.16
108.96
103.13
82.53
79.96
64.15
41.71
24.57
15.42
% Of Sales
-
1.22%
1.22%
1.25%
1.33%
1.33%
1.36%
1.29%
0.85%
0.56%
0.39%
Employee Cost
-
2,692.37
2,260.60
1,918.47
1,620.59
1,415.78
1,335.53
1,094.79
1,076.75
883.58
736.79
% Of Sales
-
22.06%
22.03%
21.93%
20.83%
22.78%
22.74%
21.98%
21.88%
20.16%
18.68%
Manufacturing Exp.
-
216.03
172.71
150.57
160.29
140.14
109.22
85.46
104.83
72.85
42.50
% Of Sales
-
1.77%
1.68%
1.72%
2.06%
2.26%
1.86%
1.72%
2.13%
1.66%
1.08%
General & Admin Exp.
-
1,314.02
939.49
1,000.80
655.99
451.75
439.00
508.16
424.35
362.38
317.44
% Of Sales
-
10.76%
9.16%
11.44%
8.43%
7.27%
7.48%
10.20%
8.62%
8.27%
8.05%
Selling & Distn. Exp.
-
1,164.71
924.26
638.11
708.17
587.73
426.72
521.81
541.84
557.66
500.10
% Of Sales
-
9.54%
9.01%
7.29%
9.10%
9.46%
7.27%
10.48%
11.01%
12.73%
12.68%
Miscellaneous Exp.
-
161.31
124.58
116.96
121.10
106.78
158.66
59.24
67.04
44.47
500.10
% Of Sales
-
1.32%
1.21%
1.34%
1.56%
1.72%
2.70%
1.19%
1.36%
1.01%
0.55%
EBITDA
3,617.41
3,020.47
2,515.17
1,901.93
1,990.55
1,649.11
1,444.71
925.03
993.65
850.95
759.08
EBITDA Margin
25.34%
24.74%
24.51%
21.74%
25.58%
26.54%
24.60%
18.57%
20.19%
19.42%
19.25%
Other Income
358.79
536.79
280.22
128.57
196.03
170.95
103.78
52.92
72.06
89.08
71.00
Interest
639.28
431.95
34.24
45.76
59.80
21.16
23.24
44.24
25.22
3.64
2.71
Depreciation
886.18
621.22
378.42
325.92
166.62
118.97
99.06
69.03
45.83
30.79
43.41
PBT
2,320.99
2,504.09
2,382.73
1,658.81
1,960.15
1,679.93
1,426.20
864.66
994.67
905.60
783.96
Tax
394.58
509.74
457.15
361.56
521.64
398.58
381.59
264.12
322.87
289.69
243.74
Tax Rate
17.00%
20.36%
19.19%
21.80%
26.61%
23.73%
26.76%
30.55%
32.46%
31.99%
31.09%
PAT
1,926.41
1,986.43
1,911.92
1,281.86
1,433.48
1,265.42
1,030.42
578.53
643.72
615.91
540.22
PAT before Minority Interest
1,901.24
2,006.59
1,940.79
1,309.68
1,452.96
1,293.03
1,056.14
610.48
671.80
615.91
540.22
Minority Interest
-25.17
-20.16
-28.87
-27.82
-19.48
-27.61
-25.72
-31.95
-28.08
0.00
0.00
PAT Margin
13.49%
16.27%
18.63%
14.65%
18.42%
20.36%
17.55%
11.62%
13.08%
14.05%
13.70%
PAT Growth
-3.41%
3.90%
49.15%
-10.58%
13.28%
22.81%
78.11%
-10.13%
4.52%
14.01%
 
EPS
46.67
48.12
46.32
31.05
34.73
30.65
24.96
14.01
15.59
14.92
13.09

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
14,332.39
9,363.09
7,435.22
6,155.23
4,722.00
3,485.31
2,823.05
2,880.91
2,927.14
2,256.95
Share Capital
41.26
40.06
40.06
40.06
40.06
40.06
40.06
40.06
20.03
20.03
Total Reserves
14,247.46
9,299.78
7,395.10
6,115.17
4,681.94
3,445.25
2,782.99
2,840.85
2,907.11
2,236.93
Non-Current Liabilities
7,419.90
187.34
199.24
168.68
107.33
103.04
77.79
49.19
53.24
34.37
Secured Loans
5,077.83
24.87
23.15
48.94
57.42
58.19
25.11
2.70
1.43
0.10
Unsecured Loans
448.36
0.00
0.00
0.25
0.25
0.00
0.00
0.34
1.25
2.29
Long Term Provisions
155.06
123.12
97.89
80.00
72.24
63.00
44.92
35.63
25.04
17.86
Current Liabilities
5,663.56
2,119.73
1,863.14
2,623.46
1,353.40
1,250.73
1,024.06
1,296.24
662.57
527.51
Trade Payables
1,133.40
777.06
1,008.18
1,076.40
666.97
745.11
561.97
649.14
491.82
419.10
Other Current Liabilities
1,335.07
755.50
386.05
472.89
282.77
180.05
116.53
161.51
140.02
100.64
Short Term Borrowings
2,513.14
151.48
115.02
794.59
158.35
44.28
241.46
404.15
9.94
0.00
Short Term Provisions
681.95
435.69
353.89
279.59
245.30
281.29
104.10
81.44
20.80
7.76
Total Liabilities
27,651.64
11,882.86
9,685.67
9,108.45
6,323.62
5,025.34
4,083.52
4,360.47
3,741.01
2,848.31
Net Block
19,004.48
4,539.95
4,245.28
3,582.77
1,658.94
1,594.04
1,399.46
1,013.77
793.31
446.98
Gross Block
20,916.96
5,909.74
5,233.03
4,246.54
2,160.04
1,987.79
1,681.37
1,229.77
915.35
488.62
Accumulated Depreciation
1,912.48
1,369.79
987.75
663.78
501.10
372.99
281.91
216.00
122.04
41.64
Non Current Assets
20,663.37
5,314.64
5,357.80
4,701.63
2,416.98
2,203.13
2,085.41
1,786.75
1,672.00
1,141.79
Capital Work in Progress
825.67
281.80
550.15
701.47
371.95
316.95
327.87
525.07
301.66
139.15
Non Current Investment
351.09
309.81
270.95
235.01
205.80
164.39
215.66
139.38
100.98
53.80
Long Term Loans & Adv.
293.08
163.97
187.54
163.88
158.07
106.06
117.69
77.10
259.59
335.97
Other Non Current Assets
189.00
13.79
98.51
13.09
16.72
16.12
14.35
8.52
9.07
6.55
Current Assets
6,985.57
6,565.52
4,324.56
4,403.84
3,879.62
2,819.50
1,943.15
2,573.71
2,069.01
1,706.53
Current Investments
1,690.84
2,258.11
1,075.47
874.46
1,306.17
665.03
543.27
649.87
847.94
655.02
Inventories
2,093.71
1,553.46
1,498.46
1,760.24
1,183.54
899.13
820.99
789.25
788.87
619.11
Sundry Debtors
1,538.34
848.28
576.42
388.17
330.61
531.09
220.22
296.67
166.46
192.71
Cash & Bank
554.50
708.10
453.20
405.94
700.74
419.88
141.01
138.95
145.87
89.58
Other Current Assets
1,108.18
104.10
64.29
170.74
358.56
304.37
217.67
698.97
119.88
150.12
Short Term Loans & Adv.
1,010.76
1,093.47
656.71
804.29
275.79
294.21
209.18
230.00
88.91
64.48
Net Current Assets
1,322.01
4,445.79
2,461.42
1,780.37
2,526.22
1,568.77
919.09
1,277.48
1,406.44
1,179.01
Total Assets
27,648.94
11,880.16
9,682.36
9,105.47
6,296.60
5,022.63
4,028.56
4,360.46
3,741.01
2,848.32

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
2,413.38
2,152.44
1,813.30
919.78
1,137.24
PBT
2,524.78
2,399.35
1,671.24
1,974.60
1,691.61
Adjustment
601.77
212.19
298.43
30.81
-5.66
Changes in Working Capital
-146.42
-17.57
166.73
-586.12
-94.63
Cash after chg. in Working capital
2,980.13
2,593.97
2,136.40
1,419.29
1,591.32
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-566.75
-441.53
-323.10
-499.51
-454.07
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-12,682.95
-2,081.69
-1,054.13
-1,369.14
-1,222.21
Net Fixed Assets
-270.57
-517.31
-591.49
-2,286.21
Net Investments
-12,468.02
-1,113.13
-576.36
-128.98
Others
55.64
-451.25
113.72
1,046.05
Cash from Financing Activity
10,232.56
5.27
-739.73
604.62
-7.81
Net Cash Inflow / Outflow
-37.01
76.02
19.44
155.26
-92.78
Opening Cash & Equivalents
382.01
304.82
283.06
127.33
219.73
Closing Cash & Equivalent
403.88
382.01
304.82
283.06
127.33

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
346.31
233.15
185.61
153.65
117.88
ROA
10.15%
18.00%
13.94%
18.83%
22.79%
ROE
16.98%
23.14%
19.27%
26.72%
31.51%
ROCE
18.32%
28.35%
23.49%
33.96%
39.97%
Fixed Asset Turnover
0.95
1.92
1.92
2.52
3.00
Receivable days
34.35
24.35
19.33
16.25
25.31
Inventory Days
52.50
52.16
65.31
66.57
61.16
Payable days
99.93
101.86
130.57
131.38
144.73
Cash Conversion Cycle
-13.08
-25.35
-45.92
-48.56
-58.26
Total Debt/Equity
0.58
0.02
0.02
0.14
0.05
Interest Cover
6.83
71.03
37.52
34.02
80.96

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Mankind Pharma’s arm acquires remaining 10% stake in Upakarma
    3rd Jun 2026, 10:30 AM

    This acquisition will enable the company to achieve better operational efficiencies through streamlined processes

    Read More
  • Mankind Pharma gets nod to invest up to Rs 500 crore in Mankind Medicare
    20th May 2026, 09:30 AM

    The Board of Directors of the Company at its meeting held May 19, 2026, has approved the same

    Read More
  • Mankind Pharma acquires ‘Rivotril’ brand from Roche for Indian market
    18th Mar 2026, 12:19 PM

    Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.